Did you know, Dymista® provides a 30 minute onset of action in clinical practice, with efficacy confirmed in real life
In a randomised, double-blind, placebo-controlled, 2-week trial involving 779 patients with moderate-to-severe seasonal allergic rhinitis, Dymista® (MP29-02) showed a rapid onset of action, with statistically significantly greater improvement in the total nasal symptom score (TNSS) compared with placebo at 30 minutes after the first dose. The significant improvements in TNSS over placebo were sustained at each subsequent evaluation point during the 4-hour observation period.'
A study assessing the use, effectiveness and safety of Dyrnista® in routine clinical practice reported that the effectiveness of Dyrnista® observed in real-world setting was better than its efficacy in randomised controlled clinical trials. Results show in real-life, a rapid clinically relevant change, the rapid and complete response is what AR patients want.2 Patients (n=1781) assessed symptom control using visual analogue scale (VAS). The study showed that Dyrnista® provides effective and rapid symptom control across all age groups (adolescents >_ 12 years, adults, and older patients) in a real-life setting with responder rates higher than those observed in controlled clinical trials.2
Dymista® provides a 30 minute onset of action in clinical practice1
Click below to hear from the experts about the 30 minute onset of action and real-life results
Further Your Understanding
Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.
Impact of Rhinitis
- Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasonepropionate) in the treatment of seasonal allergic rhinitis: a randomized, double- blind. Placebo-controlled trial of efficacy and safety. Allergy AsthmaProc. 2012; 33: 324-332.
- Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC, el al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real—life: Results from a noninterventional study. Allergy AsthmaProc. 2015; 36: 40-47.